HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Umbilical cord blood as a new and promising source of unrelated-donor hematopoietic stem cells for transplantation.

AbstractA rapidly accelerating number of transplantations of hematopoietic stem cells from human umbilical cord blood have been performed for malignancies and for congenital disorders. Umbilical cord blood presents multiple advantages over bone marrow as a source of stem cells. Harvesting presents no donor risk or discomfort, the product carries less likelihood of infectious disease transmission, and collection can be targeted to include minority groups underrepresented in bone marrow donor registries. Furthermore, the interval from initiation of a search to the transplantation procedure has been much shorter than for bone marrow, and the lack of mature T lymphocytes in cord blood reduces the incidence and severity of graft-versus-host disease in transplant recipients. Potential problems under current investigations include whether cord blood provides a sufficient quantity of stem cells for adult recipients or an effective level of "graft-versus-leukemia" effect.
AuthorsP E Newburger, P J Quesenberry (Affiliation: University of Massachusetts Medical School, Worcester 01605, USA.)
JournalCurrent opinion in pediatrics (Curr Opin Pediatr) Vol. 8 Issue 1 Pg. 29-32 (Feb 1996) ISSN: 1040-8703 [Print] UNITED STATES
PMID8680510 (Publication Type: Journal Article, Review)
Topics
  • Fetal Blood
  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Minority Groups

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD